1. Armstrong, D., Alvarez, R., Backes, F., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-may, DeRosa, M., Eisenhauer, E., Gershenson, D., Gray, H., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G., Leath, C., Leiserowitz, G., Liu, J., Zsiros, E., 2022. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (1.2023 ed., pp. OV-C-8 of 11). National Comprehensive Cancer Network, Inc., Plymouth Meeting, PA.
2. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy;Bamias;Cancer,2010
3. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors;Demetri;Clin. Cancer Res.,2022
4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials;Doebele;Lancet Oncol.,2019
5. Early detection of ovarian cancer;Elias;Hematol./Oncol. Clin. North Am.,2018